Regis Biosciences

Regis Bio (officially Regis Biosciences, Inc.) is a San Diego-based biotechnology company developing a proprietary platform for the precise, dose-dependent control of gene expression. The company's core technology, the Regulated Gene Expression System (REGIS), utilizes an orally available small molecule inducer to allow clinicians to tune the level of therapeutic protein production in vivo. This approach aims to address the safety and efficacy limitations of current genetic medicines, such as viral gene therapies and mRNA, by providing a mechanism to modulate or terminate transgene expression in response to clinical needs. Regis Bio is currently in the pre-clinical stage, focusing on the validation of its platform across multiple therapeutic areas including oncology and rare genetic disorders.